🏥 Fortis Healthcare Q2 FY 2025-26 Financial Report: Strong Growth in Revenue, Profit, and Operational Margins

Fortis Healthcare Limited (NSE: FORTIS, BSE: 532843) — one of India’s leading integrated healthcare service providers — has announced its Q2 FY 2025-26 financial results, showcasing impressive performance across its hospital and diagnostics segments. The quarter reflects a company that continues to build on strong fundamentals, operational excellence, and strategic growth investments in specialty healthcare and diagnostics expansion.

📊 Financial Performance Overview: Q2 FY 2025-26

For the quarter ended September 30, 2025 (Q2 FY26), Fortis Healthcare reported:

• Revenue from Operations: ₹2,331 crore

• Profit After Tax (PAT): ₹329 crore

• EBITDA Margin: Approximately 22.5%

• YoY Revenue Growth: ~17% compared to Q2 FY25

• QoQ Revenue Growth: ~7% compared to Q1 FY26

This strong performance demonstrates consistent growth momentum across Fortis’s hospital and diagnostics businesses. The company continues to capitalize on India’s booming healthcare demand, driven by rising chronic diseases, preventive health awareness, and increasing preference for private healthcare facilities.

💹 Comparative Financial Table: Q2 FY26 vs Q1 FY26 vs Q2 FY25

Sources: Company reports, brokerage research (Kotak, Axis Direct), BSE filings, Fortis Healthcare investor presentations.

🏨 Key Highlights of Fortis Q2 FY 2025-26 Results

1️⃣ Hospital Business — The Core Growth Driver

The hospital segment remains the backbone of Fortis Healthcare, contributing nearly 80% of total revenue.

• The hospital vertical achieved double-digit growth in both revenue and EBITDA.

• ARPOB (Average Revenue Per Occupied Bed) rose 8.9% YoY, indicating a richer specialty mix and improved realization per patient.

• Occupancy improved to 73%, driven by strong patient inflows across metro hospitals in Delhi NCR, Mumbai, and Chandigarh.

• The addition of new capacities in Manesar, Noida, and Faridabad has started yielding benefits.

Management highlighted that cardiac sciences, oncology, neurology, and orthopedics continue to drive patient inflows, with demand for elective procedures improving significantly.

2️⃣ Diagnostics Business — Strengthening Preventive Healthcare

The diagnostics segment, operating under SRL Diagnostics, showed steady performance despite intense market competition.

• The segment recorded a revenue of ₹355 crore, up 7.2% YoY.

• Growth was led by an increase in preventive health packages and digital diagnostics bookings through Fortis’s online platform.

• Margins stood at 24%, one of the highest in the Indian diagnostics industry.

Fortis aims to expand SRL’s presence by adding more than 400 new collection centers by FY 2026, focusing on Tier-II and Tier-III cities.

3️⃣ Strong Operating Leverage & Cost Control

Fortis continues to enhance operating efficiency. Cost-to-income ratios improved due to:

• Enhanced occupancy and throughput at hospitals

• Automation of administrative processes

• Energy and supply chain cost optimization

The EBITDA margin of 22.5% marks a healthy 60-basis-point improvement YoY, showcasing better scale leverage and financial discipline.

4️⃣ Healthy Balance Sheet and Low Leverage

Fortis Healthcare maintains a strong financial position with net debt of less than ₹300 crore, translating to a Net Debt/EBITDA ratio of only 0.15x.

This healthy balance sheet enables Fortis to fund expansion plans through internal accruals, reducing dependence on external borrowings.

🧠 Management Guidance and Outlook for FY 2025-26

During the earnings call, Fortis management outlined its strategic focus and guidance for the rest of FY 2025-26:

📈 Growth Targets

• Revenue Growth: 14–15% in FY26, led by hospitals and diagnostics.

• EBITDA Margin Expansion: Expected 150–200 bps improvement YoY.

• ARPOB Growth: 5–6% driven by mix of high-end specialties and better pricing realization.

🏗️ Capacity Expansion

Fortis plans to add 600+ beds in FY26 through brownfield projects, particularly in NCR and Punjab regions.
These additions are strategically aligned to meet growing demand without excessive capital burden.

💊 Diagnostics Transformation

SRL aims to grow its digital health vertical and preventive test portfolio, targeting a 10% revenue CAGR in the diagnostics segment by FY27.

🌍 Technology & Digital Health

Fortis continues investing in AI-driven diagnostics, tele-ICU systems, and digital patient management, improving service quality and patient retention.

👨‍⚕️ Focus Areas for FY26

1. Specialty care in cardiac sciences, oncology, and neurosciences.

2. Increased outpatient services through online consultations.

3. Improving bed utilization in newly expanded hospitals.

4. Sustainability initiatives and energy efficiency to reduce operational costs.

🌐 Industry Context: Healthcare Demand in India Rising Rapidly

India’s healthcare market continues to expand, with private hospital chains like Fortis benefiting from both domestic patient inflow and medical tourism.

• The Indian healthcare sector is expected to reach USD 400 billion by 2030, with a CAGR of over 16%.

• Medical tourism contributes significantly, with patients from SAARC and African nations choosing Fortis for advanced tertiary care.

• Government schemes such as Ayushman Bharat Digital Mission and insurance penetration further support private healthcare growth.

These macro factors strengthen Fortis’s outlook as a top private hospital network in India.

⚠️ Challenges Ahead

Despite strong results, Fortis must navigate a few challenges:

1. Regulatory risk: Any price caps on medical procedures or consumables could impact margins.

2. Intense competition: With Apollo, Max Healthcare, and Narayana expanding aggressively, competitive intensity remains high.

3. Rising manpower and technology costs: Sustained margin discipline will be key.

4. New hospital ramp-up risk: Brownfield additions take 18–24 months to achieve optimal occupancy.

However, given its operational efficiency, brand reputation, and diversified revenue streams, Fortis is well-equipped to mitigate these challenges.

📉 Stock Market Reaction and Investor Sentiment

Following Q2 FY26 results, Fortis Healthcare shares traded around ₹495 per share, up 65% YoY, reflecting investor confidence in the company’s strategic direction.

Analysts maintain a “BUY” rating, with target prices ranging between ₹525–₹550, citing strong visibility in earnings growth and superior return ratios.

🧾 Summary: Fortis Healthcare on a Growth Path

The Q2 FY 2025-26 financial performance cements Fortis Healthcare’s position as a leading private healthcare provider in India.
With solid hospital growth, expanding diagnostics network, and improved profitability, Fortis continues to deliver sustainable, quality-driven growth.

Key takeaways:

• Highest-ever quarterly revenue: ₹2,331 crore

• PAT growth: 87% YoY

• Margin improvement: +60 bps YoY

• Strong balance sheet with minimal debt

• Positive management guidance for FY26

As India’s healthcare demand continues to rise, Fortis Healthcare is poised for robust multi-year growth supported by expanding capacity, digital adoption, and operational excellence.